Valuation: Genexine, Inc.

Market Cap 243B 166M 146M 136M 125M 234M 16.02B 238M 1.61B 630M 7.87B 624M 611M 27.22B P/E 2022
-8.34x
P/E 2023 -5.99x
Enterprise Value 246B 168M 148M 137M 126M 237M 16.21B 241M 1.63B 638M 7.97B 632M 618M 27.55B EV / Sales 2022
33x
EV / Sales 2023 93.4x
Free-Float
86.57%
Yield 2022 *
-
Yield 2023 -
04-28 Genexine Inc Demonstrates First-In-Class Sox2 Degrader Gx-Bp1 in Preclinical Models CI
03-16 Egret Therapeutics, Inc and Genexine, Inc Sign Memorandum Of Understanding For Asset Transfer Of GX-P1 (EGT-101) CI
03-15 Egret Therapeutics Inc. signed a non-binding Memorandum of Understanding to acquire full right, title, and interest in lead asset EGT-101 (GX-P1) from Genexine, Inc.. CI
30/09/25 Genexine, Inc. announced that it has received KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
22/09/25 Genexine, Inc. announced that it expects to receive KRW 19.4 billion in funding from Mirae Asset Securities Co., Ltd., Ds Investment & Securities Co.,Ltd., Synergy IB Investment Co., Ltd., Synergy-Premier Mezzanine Blind No. 1 New Technology Business Investment Fund, BNK Securities Co.,Ltd., Korea Investment & Securities Co., Ltd. CI
07/03/25 Boehringer Ingelheim Ends Development of Steatohepatitis Drug, Returns Rights to Yuhan MT
30/09/24 Genexine, Inc. completed the acquisition of EPD Biotherapeutics Inc. CI
04/07/24 Genexine, Inc. Appoints Jaehyun Choi as Head of R&D CI
25/06/24 Genexine, Inc. signed a letter of intent to acquire EPD Biotherapeutics Inc. for KRW25.6 billion. CI
14/05/24 Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
14/11/23 Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
23/10/23 Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority CI
31/08/23 Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday MT
1 day+1.85%
1 week+5.32%
Current month-1.98%
1 month+1.02%
3 months-56.43%
6 months-46.14%
Current year-47.17%
1 week 2,230
Extreme 2230
2,545
1 month 2,140
Extreme 2140
2,670
Current year 2,140
Extreme 2140
7,490
1 year 2,140
Extreme 2140
7,490
3 years 2,140
Extreme 2140
12,300
5 years 2,140
Extreme 2140
73,692.31
10 years 2,140
Extreme 2140
146,384.62
Manager TitleAgeSince
Chief Executive Officer 51 25/03/2025
Chief Executive Officer 61 26/01/2023
Corporate Officer/Principal 49 31/12/2021
Director TitleAgeSince
Chairman 68 -
Director/Board Member 74 28/03/2022
Director/Board Member 61 26/01/2023
Date Insider Type Main position Quantity % Market Cap.
22/10/24 Others 156,632 0.3773%
22/10/24 Others

Chief Executive Officer

1,691,165 4.0741%
22/10/24 Others 563,723 1.3580%
Change 5-day change 1-year change 3-year change Capi.($)
+1.85%+5.32%-54.34%-73.27% 77.08M
+0.93%+6.97%+59.60%+68.35% 57.28B
-1.92%+6.03%+40.64%+83.42% 54.99B
-0.46%-1.29%+2.86%+428.78% 23.18B
-2.97%-2.35%-22.53%-16.40% 22.59B
-0.36%+5.73%+24.13%-6.24% 20.46B
-1.34%+0.51%+26.03%-29.41% 17.56B
-1.44%+5.67%+38.77%+504.71% 15.67B
-1.30%-5.02%+170.77%+291.37% 14.46B
-0.50%-0.98%+21.43%+180.07% 13.92B
Average -0.75%+1.96%+30.74%+143.14% 24.02B
Weighted average by Cap. -0.87%+2.10%+39.67%+133.43%

Financials

2022 2023
Net sales 16.14B 11.05M 9.71M 9.03M 8.28M 15.56M 1.06B 15.8M 107M 41.88M 523M 41.49M 40.59M 1.81B 4.43B 3.03M 2.66M 2.48M 2.27M 4.27M 292M 4.33M 29.4M 11.49M 144M 11.38M 11.13M 496M
Net income -55.97B -38.33M -33.66M -31.31M -28.73M -53.98M -3.69B -54.81M -372M -145M -1.81B -144M -141M -6.27B -66.87B -45.79M -40.22M -37.4M -34.32M -64.49M -4.41B -65.48M -444M -174M -2.17B -172M -168M -7.5B
Net Debt 62.14B 42.55M 37.37M 34.76M 31.89M 59.93M 4.1B 60.85M 413M 161M 2.01B 160M 156M 6.97B 2.94B 2.02M 1.77M 1.65M 1.51M 2.84M 194M 2.88M 19.56M 7.64M 95.48M 7.57M 7.41M 330M
Logo Genexine, Inc.
Genexine Inc is a Korea-based company mainly engaged in the research and development of bio pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. It also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.
Employees
86
Date Price Change Volume
24/07/26 ₩2,475.00 +1.85% 74,870
23/07/26 ₩2,430.00 +3.85% 88,268
22/07/26 ₩2,340.00 -0.64% 61,053
21/07/26 ₩2,355.00 +2.84% 84,503
20/07/26 ₩2,290.00 -2.55% 69,586
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A095700 Stock